Buy 2 AI-Powered Technology Services Stocks to Tap Lucrative Upside
The Zacks-defined Technology Services industry currently ranks within the top 16% of Zacks Ranked Industries. Consequently, we expect it to outperform the market over the next three to six months. We recommend two artificial intelligence (AI)-powered technology services bigwigs with a top Zacks Rank and solid price upside in the short term.
These two stocks are: AppLovin Corp. APP and Duolingo Inc. DUOL. Each of our picks currently carries either a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Technology Services Industry Thriving
The global shift toward digitization creates opportunities in various markets, including 5G, blockchain and AI. Companies are adopting generative AI, machine language (ML), blockchain and data science faster to gain a competitive advantage.
The business software industry is gaining from robust demand for multi-cloud-enabled software solutions, given the ongoing transition from legacy platforms to modern cloud-based infrastructure.
Industry players are incorporating AI and ML into their applications to achieve more dynamic and result-oriented outcomes. Elevated demand for enterprise software, which is ramping up productivity and improving the decision-making process, is a key catalyst.
AppLovin Corp.
Zacks Rank #1 AppLovin is engaged in building a software-based platform for mobile app developers to enhance the marketing and monetization of their apps in the United States and internationally. APP provides a technology platform that enables developers to market, monetize, analyze and publish their apps.
AppLovin's last reported financial results demonstrate its strong fundamentals and growth potential. The introduction of APP's AI-powered AXON 2.0 technology and strategic expansion in gaming studios have significantly boosted revenue growth. APP's AI-enabled Audience+ marketing platform is also increasing its reach into the direct-to-consumer and e-commerce space.
Huge Price Upside Potential for APP Shares
The average short-term price target of brokerage firms represents an increase of 37% from the last closing price of $341.64. The brokerage target price is currently in the range of $200-$650. This indicates a maximum upside of 90.3% and a downside of 41.5%.
AppLovin has an expected revenue and earnings growth rate of 16% and 84.8%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.1% in the last seven days.
Duolingo Inc.
Zacks Rank #2 Duolingo operates as a mobile learning platform in the United States, China, the United Kingdom, and internationally. DUOL offers courses in 40 different languages through the Duolingo app. Moreover, DUOL provides a digital language proficiency assessment exam.
Duolingo utilizes several AI applications to personalize and automate learning process, error analyzing and content creation. Its Birdbrain AI system analyze real-time user performance. DUOL uses OpenAI's large language models for content creation.
Solid Price Upside Potential for DUOL Stock
The average short-term price target of brokerage firms represents an increase of 24% from the last closing price of $391.86. The brokerage target price is currently in the range of $375-$600. This indicates a maximum upside of 53.1% and a downside of 4.3%.
DUOL has an expected revenue and earnings growth rate of 33.5% and 54.3%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 2.1% over the last 60 days.
Image Source: Zacks Investment Research
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AppLovin Corporation (APP): Free Stock Analysis Report
Duolingo, Inc. (DUOL): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
9 minutes ago
- National Post
Realbotix Integrates Multiple Languages into AI, Unlocking Global Customer Service Applications
Article content LAS VEGAS — Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (' Realbotix ' or the 'Company'), a leader in AI-powered humanoid robotics, announces that its robot now communicates fluently in 15 major languages, with access to more than 147 additional languages and dialects through cloud-based support. This multilingual capability enhances Realbotix's robots ability to connect with people across a wide range of industries and cultural contexts. Article content With its expanded language support and ability to integrate most third party AI platforms, the robot is well suited for international venues such as airports, hotels, museums, and tourist attractions. It can provide information, answer questions, and assist visitors in the language they are most comfortable speaking, improving accessibility and overall guest experience. Lifelike in both appearance and interaction, the Realbotix robot is designed to deliver natural and engaging conversations. Article content In healthcare settings, the robot can serve as a communication bridge between patients and medical staff. Patients can speak in their preferred language, allowing them to ask questions, describe symptoms, or share concerns. The robot then translates the information and relays it to healthcare teams, helping to ensure clearer communication and more responsive care. Article content 'Adding multilingual support to our humanoid robot is a meaningful step toward more human-centered technology,' said Andrew Kiguel, CEO of Realbotix. 'Whether in a hospital or a hotel, the ability to understand and respond in someone's native language builds trust and makes the experience more personal.' Article content Realbotix continues to enhance its AI platform with advanced speech, emotional recognition, and lifelike interaction, offering customizable robotic solutions for industries including hospitality, healthcare, and customer service. Article content Realbotix designs and manufactures AI -powered humanoid robots that improve human experiences through connection, companionship and intelligent interaction. Article content Manufactured in the United States, Realbotix specializes in realistic, customizable robots built for entertainment, customer service, and personal well-being. Our patented AI and robotics technologies enable lifelike expression, motion, and social engagement, making us a category leader in the rapidly evolving field of human-centric robotics. Article content Article content : Product site Article content Article content Article content : Corporate and Investor site Article content Keep up-to-date on Realbotix developments by joining our online communities on Twitter, LinkedIn, and YouTube. Article content Forward-Looking Statements Article content This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as 'may', 'will', 'plan', 'expect', 'anticipate', 'estimate', 'intend' and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, as described in more detail in our securities filings available at Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Article content Article content Article content Article content Contacts Article content Article content
Globe and Mail
27 minutes ago
- Globe and Mail
The Zacks Analyst Blog Highlights Heico, Dell Technologies and ENGIE
For Immediate Release Chicago, IL – July 7, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Heico HEI, Dell Technologies DELL and ENGIE Sponsored ADR ENGIY. Here are highlights from Thursday's Analyst Blog: Tariff Effects Have Landed: Zacks July Market Strategy The following is an excerpt from Zacks Chief Strategist John Blank's full Jul Market Strategy report To access the full PDF, click here. Think there are no signs of tariffs inside the current U.S. macro system? Think again! I. Introduction Each month, I highlight a section found within the latest Zacks Market Strategy report. In the month of JULY? I highlight the Institute of Supply Management's (ISM) manufacturing purchasing manager indices (PMI). Striking tariff dynamics caught my attention! Note: 50 is the rubicon between expansion and contraction. (1) The ISM Prices sub-index at 69.7 is consistent with higher tariffs. (2) These five ISM sub-indices are also consistent with a higher tariff regime: · New Orders at 46.4 · Backlog of Orders at 44.3 · New Export Orders at 46.3 · Imports at 47.4, and · Employment at 45.0 Most are contracting for the last 4 to 5 months. That too is consistent with policy actions. (3) Finally, every single ISM respondent mentioned tariffs in their response. Carefully read what is written, by the various purchasing managers. II. WHAT ISM RESPONDENTS ARE SAYING 'Business has notably slowed in last four to six weeks. Customers do not want to make commitments in the wake of massive tariff uncertainty.' [Fabricated Metal Products] 'Middle East unrest as well as unstable long-term tariff positions continue to impact second- and third-tier sources, which is applying pressure to material costs. Costs are up 6 percent to 10 percent over budgeted inflation — and the forecast accounted for the volatility expected with the current administration.' [Wood Products] 'The biopharmaceutical space is starting to see more pronounced headwinds: Stock prices have significantly eroded, companies are facing hiring freezes, and so on.' [Chemical Products] 'The tariff mess has utterly stopped sales globally and domestically. Everyone is on pause. Orders have collapsed.' [Machinery] 'Tariff volatility has impacted machinery, steel and specialized components. Also, potential shortages of skilled labor for construction, maintenance and installation.' [Food, Beverage & Tobacco Products] 'Tariffs continue to cause confusion and uncertainty for long-term procurement decisions. The situation remains too volatile to firmly put such plans into place.' [Computer & Electronic Products] 'Tariffs continue to impact material pricing.' [Petroleum & Coal Products] 'Tariffs, chaos, sluggish economy, rising prices, Ukraine, Iran, geopolitical unrest around the world — all make for a landscape that is hellacious, and fatigue is setting in due to dealing with these issues across the spectrum. Unfortunately, this is just the beginning unless something drastically changes, but the supply chain implications will grow — depots will not be stocked, less material will be available, and it will take years for domestic production to handle the needs (if companies even want to).' [Primary Metals] 'The geopolitical environment remains volatile: (1) ongoing shifts in U.S. tariff policy make it difficult to plan, (2) emerging conflicts in the Middle East could pose long-term commodity risks and (3) China measures on rare earth materials are causing challenges. Overall outlook for our company is positive; it's just extremely hard to make near-term supply plans/strategies or budgets.' [Miscellaneous Manufacturing] 'The word that best describes the current market outlook is 'uncertainty.' The erratic trade policy with on-again/off-again tariffs has led to price uncertainty for customers, who appear to be prepared to hold off large capital purchases until stability returns. This has resulted in further reductions in customer demand and softening sales for the balance of 2025. Operations has planned additional weeks of downtime at multiple plants to accommodate reduced orders. Next year's forecast is not any better at this point. Additionally, most electric vehicle (EV) projects have been delayed or canceled, resulting in a significant amount of unutilized capital investment. EV technology launches for 2026-28 have been delayed past 2030.' [Transportation Equipment] Now, let's study the latest Zacks Industry Ranks. These mid-summer rankings turned out to be surprisingly strong. III. Zacks JULY 2025 Sector/Industry/Company Telescope June 30th, 2025 data showed a positive pre-Q2 earnings Zacks Industry Ranking. This supplies three Very Attractive Sectors: Industrials, Info Tech, & Utilities. Info Tech (and likely Utilities) earnings growth is well-supported by 'AI' data/cloud centers and strong tech mega-cap earnings. Four sectors are now at Attractive: Consumer Staples fell to Attractive. Financials and Materials stayed at Attractive. Communication Services rose to Attractive. Health Care stayed on at an Unattractive rating. Consumer Discretionary and Energy sectors held onto Very Unattractive ratings. (1) Industrials stayed at Very Attractive. Aerospace & Defense, Pollution Control, Business Products, and Business Services looked strong. Zacks #1 Rank (STRONG BUY): Heico. An FAA-approved jet engine and aircraft component replacement parts. (2) Info Tech rose to Very Attractive from Attractive. Misc. Tech and Electronics led. Zacks #1 Rank (STRONG BUY): Dell Technologies. A leading provider of servers, storage and PCs. (3) Utilities rose to Very Attractive from Attractive. Utility-Water Supply looked the best. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dell Technologies Inc. (DELL): Free Stock Analysis Report Heico Corporation (HEI): Free Stock Analysis Report ENGIE - Sponsored ADR (ENGIY): Free Stock Analysis Report
Globe and Mail
28 minutes ago
- Globe and Mail
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on hematologic malignancies, where he served as CFO since 2022. 'Babar brings extensive deal making and operational experience in addition to his previous roles as a CFO at rare disease companies. The addition of these skills and expertise to the leadership team are exactly what we need at this time as we look to deploy capital and accelerate our path to sustainable growth and increasing value that continues well into the next decade,' said Jon Stonehouse, chief executive officer of BioCryst. Previously, Mr. Ghias was executive vice president of investments and portfolio management at Paragon Biosciences, a global biotech development firm. He also served as chief financial and operating officer for several Paragon portfolio companies. At Paragon, he launched four biotechnology companies focused on rare diseases from early clinical to successful commercial launch. From 2014 to 2017, he served as CFO and head of corporate development at Marathon Pharmaceuticals, a specialty rare disease company, where he prepared the company for a commercial launch and led the successful sale of the firm. Mr. Ghias has raised over $1 billion in capital for the companies he has been involved with. Earlier in his career, for over a decade, he was an investment banker who served as a senior member of the mergers and acquisitions team at Credit Suisse, providing strategic advice to clients and boards of directors in the healthcare and life sciences industries and successfully closing over $80 billion in transactions. 'I am thrilled to join BioCryst at such a pivotal time in its growth journey. The strong commercial momentum from ORLADEYO alongside the advancing pipeline and the opportunity to deploy capital behind new growth initiatives present an enormous opportunity for building long term value. I look forward to partnering with the leadership team to drive operational excellence and financial discipline, and support our ambitious growth plans,' Ghias said. Mr. Ghias earned his M.B.A. with honors from Washington University in St. Louis and holds a B.S. in economics from Lahore University of Management Sciences in Pakistan. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding future results, performance, achievements, plans and expectations regarding BioCryst's growth, capital deployment, and pipeline. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst's ability to successfully implement or maintain its commercialization plans for ORLADEYO; BioCryst's ability to successfully progress its pipeline development plans; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance and demand; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst's ability to successfully commercialize its products and product candidates; BioCryst's ability to successfully manage its growth and compete effectively; timing for achieving and sustainability of profitability and positive cash flow may not meet management's expectations; statements regarding financial goals and the attainment of such goals may differ from actual results based on market factors and BioCryst's ability to execute its operational, capital deployment and budget plans; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst's projections and forward-looking statements. BCRXW
